NCT03350451 - An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

February 7, 2023

Study Completion Date

February 7, 2023

Conditions

PH1Primary HyperoxaluriaRNAi TherapeuticsiRNAAGT

Interventions

DRUG

Lumasiran

Multiple doses of lumasiran by SC injection

Trial Locations (9)

Clinical Trial Site, Bordeaux

Clinical Trial Site, Lyon

Clinical Trial Site, Paris

Clinical Trial Site, Bonn

Clinical Trial Site, Haifa

Clinical Trial Site, Jerusalem

Clinical Trial Site, Amsterdam

Clinical Trial Site, Birmingham

Clinical Trial Site, London